Compare CHR & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | PTIX |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.2M |
| IPO Year | N/A | 2016 |
| Metric | CHR | PTIX |
|---|---|---|
| Price | $0.04 | $1.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 60.7M | 106.6K |
| Earning Date | 07-30-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $147,134,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.03 | $1.46 |
| 52 Week High | $2.97 | $14.28 |
| Indicator | CHR | PTIX |
|---|---|---|
| Relative Strength Index (RSI) | 29.21 | 33.67 |
| Support Level | $0.04 | $1.46 |
| Resistance Level | $0.06 | $1.70 |
| Average True Range (ATR) | 0.01 | 0.18 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 34.95 | 20.65 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerReal, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.